Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

作     者：Zhifei Li Huan Zhao Huihui Hu Haili Shang Yongjing Ren Wenhui Qiu Hao Su Huifang Lyu Xiaobing Chen Zhifei Li;Huan Zhao;Huihui Hu;Haili Shang;Yongjing Ren;Wenhui Qiu;Hao Su;Huifang Lyu;Xiaobing Chen

作者机构：Department of Oncologythe Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer HospitalHenan Engineering Research Center of Precision Therapy of Gastrointestinal CancerZhengzhou Key Laboratory for Precision Therapy of Gastrointestinal CancerZhengzhou 450008China Henan University of Traditional Chinese MedicineZhengzhou 450046China State Key Laboratory of Esophageal Cancer Prevention&TreatmentKey Laboratory of Advanced Drug Preparation TechnologiesMinistry of EducationSchool of Pharmaceutical SciencesZhengzhou UniversityZhengzhou 450001China The First Affiliated Hospital of Xinxiang Medical UniversityXinxiang 453000China Department of Oncologythe Affiliated Cancer Hospital of Zhengzhou University&Henan Cancer HospitalZhengzhou 450008China 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2024年第36卷第3期

页      面：306-321页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the Project of Henan Provincial Medical Science and Technology Research Plan(No.SBGJ202301004 and No.LHGJ20210186) the Key Science Fund project of Henan Provincial Natural Science Foundation(No.232300421119) 

主　　题：HER2 gastric cancer trastuzumab drug resistance 

摘      要：Gastric cancer is one of the most prevalent cancers worldwide,and human epidermal growth factor receptor 2(HER2)-positive cases account for approximately 20%of the total ***,trastuzumab+chemotherapy is the recommended first-line treatment for patients with HER2-positive advanced gastric cancer,and the combination has exhibited definite efficacy in HER2-targeted ***,the emergence of drug resistance during treatment considerably reduces its effectiveness;thus,it is imperative to investigate the potential mechanisms underlying *** the present review article,we comprehensively introduce multiple mechanisms underlying resistance to trastuzumab in HER2-positive gastric cancer cases,aiming to provide insights for rectifying issues associated with resistance to trastuzumab and devising subsequent treatment strategies.